Amaurosis fugax caused by heritable thrombophilia-hypofibrinolysis in cases without carotid atherosclerosis: Thromboprophylaxis prevents subsequent transient monocular partial blindness

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 2, 2007, Pages 124-129

  Glueck, Charles J ^a,c   Golnik, Karl ^b   Ping Wang, ^a  

^a JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c Cholesterol Center   (United States)

Author keywords

Amaurosis fugax; Hypofibrinolysis; Thrombophilia; Thromboprophylaxis; Transient cerebral ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; CYANOCOBALAMIN; ENOXAPARIN; FOLIC ACID; LIPOPROTEIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; PYRIDOXINE; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; HETEROZYGOSITY; HUMAN; MALE; MUTATION; PARTIAL BLINDNESS; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; THROMBOPHILIA; TRANSITIONAL BLINDNESS;

AMAUROSIS FUGAX; BLOOD COAGULATION DISORDERS; CAROTID ARTERY DISEASES; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MALE; THROMBOPHILIA;

EID: 34047258489     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606298735     Document Type: Article

References (27)

1. Babikian V., Wijman CA, Koleini B., Malik SN, Goyal N., Matjucha IC Retinal ischemia and embolism. Etiologies and outcomes based on a prospective study. Cerebrovasc Dis. 2001 ; 12: 108-113.
2. Iwamoto T., Matsushima C., Shimizu S., Takasaki M., Iwasaki T., Usui M. [Carotid ultrasonographic and brain computerized tomographic findings in patients with vascular ocular syndromes]. No To Shinkei. 2002 ; 54: 119-125.
3. Nguyen TN, Gans MS, Cote R. The prognosis of amaurosis fugax and hemispheric transient ischemic attacks. Can J Ophthalmol. 1999 ; 34: 210-216.
4. Donders RC Clinical features of transient monocular blindness and the likelihood of atherosclerotic lesions of the internal carotid artery. J Neurol Neurosurg Psychiatry. 2001 ; 71: 247-249.
5. Tegos TJ, Sabetai MM, Nicolaides AN, et al. Patterns of cerebrovascular symptomatology associated with carotid atheroma. Eur J Neurol. 2000 ; 7: 499-508.
6. Pope JM, Canny CL, Bell DA Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med. 1991 ; 90: 299-309.
7. Vrethem M., Ernerudh J., Lindstrom F., Olsson JE Cerebral ischemia associated with anticardiolipin antibodies. Acta Neurol Scand. 1992 ; 85: 412-417.
8. Lawrence PF, Oderich GS Ophthalmologic findings as predictors of carotid artery disease. Vasc Endovascular Surg. 2002 ; 36: 415-424.
9. Glueck CJ, Goldenberg N., Bell H., Golnik K., Wang P. Amaurosis fugax: associations with heritable thrombophilia. Clin Appl Thromb Hemost. 2005 ; 11: 235-241.
10. Palmowski AM, Ruprecht KW [Amaurosis fugax]. Fortschr Med. 1992 ; 110: 531-535.
11. Derieux L., Guyomard JL, Catier A., et al. [Fibrinolysis in the treatment of the amaurosis fugax: a case report]. J Fr Ophtalmol. 2003 ; 26: 507-509.
12. Eriksson SE Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. Acta Neurol Scand. 1985 ; 71: 485-493.
13. Bick RL, Alfar H., Goedecke C. Thrombophilic causes of retinal vascular thrombosis: etiology and treatment outcomes. Clin Appl Thromb Hemost. 2002 ; 8: 315-318.
14. Goertler M., Blaser T., Krueger S., Hofmann K., Baeumer M., Wallesch CW Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke. J Neurol Neurosurg Psychiatry. 2002 ; 72: 338-342.
15. Olsson JE, Brechter C., Backlund H., et al. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke. 1980 ; 11: 4-9.
16. Greiner K., Peetz D., Winkgen A., Prellwitz W., Pfeiffer N., Hafner G. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol. 1999 ; 23: 155-160.
17. Soria JM, Almasy L., Souto JC, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood. 2003 ; 101: 163-167.
18. Graf LL, Welsh CH, Qamar Z., Marlar RA Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol. 2003 ; 119: 52-60.
19. Elishkewitch K., Berliner S., Eldor A., Shapira I. [High factor VIII as a risk factor for venous thrombosis]. Harefuah. 2001 ; 140: 1122-1124, 1232.
20. Cakmak S., Derex L., Berruyer M., et al. Cerebral venous thrombosis: clinical outcome and systematic screening of prothrombotic factors. Neurology. 2003 ; 60: 1175-1178.
21. Keijzer MB, den Heijer M., Blom HJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost. 2002 ; 88: 723-728.
22. Glueck CJ, Wang P., Bell H., Rangaraj V., Goldenberg N. Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation. J Lab Clin Med. 2004 ; 143: 184-192.
23. Glueck CJ, Fontaine RN, Wang P. Interaction of heritable and estrogen-induced thrombophilia: possible etiologies for ischemic optic neuropathy and ischemic stroke. Thromb Haemost. 2001 ; 85: 256-259.
24. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med. 1999 ; 130: 14-22.
25. Balasa VV, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost. 1999 ; 81: 739-744.
26. Glueck CJ, Glueck HI, Tracy T., Speirs J., McCray C., Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism. 1993 ; 42: 236-246.
27. Velazquez EM, Mendoza SG, Wang P., Glueck CJ Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the poly-cystic ovary syndrome. Metabolism. 1997 ; 46: 454-457.